What question did this study set out to answer?

To evaluate the efficacy of tirzepatide in treating metabolically dysfunctional-associated steatohepatitis (MASH).

April 13, 2026Open Access

Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review

Key Points

To evaluate the efficacy of tirzepatide in treating metabolically dysfunctional-associated steatohepatitis (MASH).
Conducted a bibliometric analysis of existing literature on tirzepatide for MASH.
Reviewed current evidence regarding the metabolic and hepatic effects of tirzepatide.
Assessed the need for further long-term studies, including phase III trials.
Tirzepatide demonstrates significant metabolic effects and hepatic improvements.
Current findings position tirzepatide as promising for metabolic liver disease management.
Long-term efficacy and phase III data remain necessary to confirm benefits.

Abstract

Tirzepatide combines potent metabolic effects with significant hepatic improvements, positioning it as a promising therapy for MASLD/MASH. Although long-term and phase III data are still needed, current evidence supports tirzepatide as a key component of modern metabolic liver disease management.

Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review

Key Points

Abstract

Cite This Study